Bayer and Hologic, Inc., today announced an international partnership to deliver contrast-enhanced-mammography (CEM) solutions to improve the detection of breast cancer in multiple countries across Canada, the European and Asia Pacific regions.
CEM is an innovative highly sensitive and low-cost breast imaging modality which combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions.
Researchers say a lot more work is needed, but their findings suggest the technology could one day support doctors working in emergency medicine, potentially leading to shorter waiting times for patients.
For over 30 years, screening mammography has been an important key in reducing breast cancer mortality rates.
13 - 16 November 2023, Düsseldorf, Germany.